報價延遲最少15分鐘:2026/09/04 15:27 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
102.485 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.12/-0.03
|
|
企業價值
7.23B
|
| 資產負債 |
|
每股賬面淨值
1.50
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
189.76M
|
|
每股收益
0.64
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International. |
